Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
- CD&R, PAI look to exclude aspects of Gold Bond unit in bids
- Consumer business could be valued at €15 billion in a sale
The Sanofi headquarters in Paris.
Photographer: Nathan Laine/BloombergThis article is for subscribers only.
Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder, according to people with knowledge of the matter.
French pharmaceutical company Sanofi had asked suitors to revise their proposals for the Opella business, Bloomberg News reported earlier this week. The new bids may exclude parts of the Gold Bond business, a brand that historically sold talc-based products, or seek to leave any future legal risks with Sanofi, said the people.